The company uses cellular engineering to produce female reproductive cell lines and has developed a platform to advance a portfolio of cellular therapeutics for female reproductive diseases. Their first program, Fertilo, aims to make IVF and egg freezing shorter, safer, and more effective. They also have additional applications of their platform, including an organoid of the female reproductive system, Deovo, and a cell-based therapeutic to ameliorate the health consequences of primary ovarian insufficiency and menopause, Ameno.